Prev Chronic Dis by Schenck, Anna P. et al.
VOLUME 8: NO. 5, A109 SEPTEMBER 2011
Physician Visits and Colorectal Cancer 
Testing Among Medicare Enrollees in 
North Carolina and South Carolina, 2005
ORIGINAL RESEARCH
Suggested citation for this article: Schenck AP, Klabunde 
CN, Warren JL, Jackson E, Peacock S, Lapin P. Physician 
visits and colorectal cancer testing among Medicare 
enrollees in North Carolina and South Carolina, 2005. 
Prev Chronic Dis 2011;8(5):A112. http://www.cdc.gov/pcd/
issues/2011/sep/10_0227.htm. Accessed [date].
PEER REVIEWED
Abstract
Introduction
Many Medicare enrollees do not receive colorectal cancer 
tests at recommended intervals despite having Medicare 
screening coverage. Little is known about the physician 
visits of Medicare enrollees who are untested. Our study 
objective was to evaluate physician visits of enrollees 
who lack appropriate testing to identify opportunities to 
increase colorectal cancer testing.
Methods
We used North Carolina and South Carolina Medicare 
data to compare type and frequency of physician visits 
for Medicare enrollees with and without a colorectal can-
cer test in 2005. Type of physician visit was defined by 
the physician specialty as primary care, mixed specialty 
(more than 1 specialty, 1 of which was primary care), and 
nonprimary care. We used multivariate modeling to assess 
the influence of type and frequency of physician visits on 
colorectal cancer testing.
Results
Approximately half (46.5%) of enrollees lacked appropri-
ate colorectal cancer testing. Among the untested group, 
19.8% had no physician visits in 2005. Enrollees with pri-
mary care visits were more likely to be tested than those 
without a primary care visit. Many enrollees who had pri-
mary care visits remained untested. Enrollees with visits 
to all physician types had a greater likelihood of having 
colorectal cancer testing.
Conclusions
We identified 3 categories of Medicare enrollees with-
out appropriate colorectal cancer testing: those with no 
visits, those who see primary care physicians only, and 
those with multiple visits to physicians with primary 
and nonprimary care specialties. Different strategies are 
needed for each category to increase colorectal cancer test-
ing in the Medicare population.
Introduction
Costs associated with colorectal cancer (CRC) are pro-
jected to be between $11.4 and $14 billion in 2020, creat-
ing a substantial burden for Medicare enrollees and the 
Medicare program (1). Illness and death associated with 
CRC can be reduced through early detection and treat-
ment. Four recommended tests for CRC screening of 
persons of average risk (2) are covered under Medicare: 1) 
annual fecal occult blood testing (FOBT); 2) sigmoidoscopy 
or 3) barium enema every 4 years; or 4) colonoscopy every 
10 years. Despite having Medicare coverage for CRC tests, 
less than half of Medicare enrollees have received CRC 
tests at the recommended intervals (3). 
Much debate about health care reform centered on provid-
ing health insurance coverage to uninsured Americans. 
Although lack of insurance coverage is a leading reason 
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for lack of access to health care, insurance coverage does 
not ensure access to health care. Aday et al (4) have used 
the term “realized access” to highlight the importance of 
factors in addition to insurance coverage and availability 
of providers that influence consumer access to health care, 
including the “transactions between patients and provid-
ers during the process of care delivery.”
Physician influence on patients’ CRC screening status is 
well documented. Physician recommendation has been 
associated with increased likelihood of screening (5,6), and 
the lack of recommendation has been identified as a barri-
er (7,8). Having a recent well visit (6), being seen in group 
practices rather than solo practices (9), and visiting inter-
nal medicine physicians rather than other primary care 
providers (10) have all been linked with increased CRC 
testing. Understanding physicians’ influence on the CRC 
screening status of Medicare enrollees is, however, compli-
cated by the fragmented care received by most Medicare 
enrollees. One study showed that most Medicare enrollees 
see 7 physicians in 4 practices in a given year (9).
The objective of this study was to examine the role of phy-
sician visits among Medicare enrollees with and without 
CRC testing — enrollees who access this preventive ser-
vice and enrollees with “unrealized access.” Our aim was 
to identify potential opportunities to increase CRC testing 
in the untested population.
Methods
Study population
In this study, we included North Carolina and South 
Carolina Medicare enrollees aged 65 to 85 as of January 
1, 2005. We limited analyses to enrollees with at least 11 
months of Part B Medicare coverage during calendar years 
2004 and 2005, and no health management organization 
(HMO) enrollment. We excluded people with a diagnosis of 
CRC on any Medicare claim in the year before their CRC 
test or in 2004 for enrollees with no test (n = 5,614), people 
with selected medical conditions (Appendix A) considered 
to confer higher risk for CRC (n = 4,734), and people with 
more than 100 physician visits in the year of observation (n 
= 20). This study was completed at The Carolinas Center 
for Medical Excellence under the Quality Improvement 
Contract for the States of North and South Carolina and 
therefore needed no institutional review board approval.
Data sources
From Medicare’s Enrollment Database, we obtained demo-
graphic information, reason for entitlement (age or dis-
ability), Part B and HMO enrollment, state of residence, 
and eligibility for state buy-in (Medicaid). To identify 
health services, we used a summary file available to qual-
ity improvement organizations containing claims for all 
services from physician offices, clinics, and hospitals and 
a unique physician identification number (UPIN). We 
used the disease and procedure codes on 2004 inpatient 
Medicare claims and evaluation and management outpa-
tient Medicare claims to create a comorbidity index for the 
study group, following a method developed by Klabunde 
and colleagues (11). We calculated a comorbidity score for 
each enrollee by summing the count of the disease flags, 
weighting clinical conditions equally. We classified enroll-
ees without eligible claims as having unknown comorbid-
ity status.
Classification of enrollee CRC test use
To identify CRC tests (FOBT, sigmoidoscopy, colonoscopy, 
and barium enema) in 2005, we used Medicare claims 
from all clinical settings according to procedure codes 
(Appendix B) and dates of service listed on the claims. 
We included diagnostic and screening procedures because 
the reason for the test cannot be reliably determined from 
Medicare claims (12,13). To ascertain CRC testing before 
2005, we reviewed Medicare claims from 1998 through 
2004 for colonoscopy, and from 2000 through 2004 for sig-
moidoscopy or barium enema. We classified patients with 
endoscopies during these intervals as compliant with no 
CRC testing needed in 2005. We classified enrollees who 
received any Medicare-covered CRC test in 2005 as receiv-
ing a CRC test in 2005. If we found no previous CRC test, 
and no test in 2005, we classified enrollees as not tested in 
2005 with no evidence of being current with CRC testing.
Classification of physician specialty
We identified physician specialty by linking UPINs to the 
Centers for Medicare and Medicaid Services Physician 
Specialty table, which contains up to 3 specialties per 
physician. We classified physician specialties as primary 
care, mixed specialty, or nonprimary care. We grouped 
internal medicine, family medicine, general practice, pre-
ventive medicine, geriatric medicine, obstetrician/gyne-
cologists, nurse practitioners, and physician assistants 
under primary care. We classified physicians with more 
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than 1 specialty designation, 1 of which was primary care 
(for example, internal medicine and cardiology) as mixed 
specialty. We classified physicians with only nonprimary 
care specialties as nonprimary care. We limited analysis 
to visits with medical doctors, doctors of osteopathy, nurse 
practitioners, physician assistants, certified clinical nurse 
specialists, and family nurse practitioners, which included 
97% of all visits in the applicable study windows.
Calculating physician visits
We were interested in the physician visits during the year 
before CRC testing. For enrollees with a CRC test in 2005, 
we examined the 12 months before the date of the CRC 
test; for noncompliant enrollees who had no CRC test, we 
used claims for the calendar year 2004 to calculate the 
frequency of physician visits. We used the term “physician 
visits” for both doctor and nurse practitioner or physician 
assistant visits. We excluded visits for critical care and 
visits to physicians with specialties not involving patient 
contact (eg, radiology). We excluded visits with physi-
cians whose specialty could not be determined, such as 
those with bad UPINs or out-of-state physicians (3.5% of 
visits). Only 1 visit per day was counted for each physi-
cian–patient encounter.
We classified enrollees on the basis of specialties of the 
physicians they visited according to the following 7 catego-
ries: 1) only primary care physicians; 2) only nonprimary 
care physicians; 3) physicians with mixed specialties (1 
of which was a primary care specialty); 4) both primary 
care and mixed-specialty physicians; 5) both primary care 
and nonprimary care physicians; 6) mixed-specialty and 
nonprimary care physicians; and 7) primary care, nonpri-
mary care, and mixed-specialty physicians.
Statistical analyses
We present demographic and enrollment characteristics 
for the 3 groups of enrollees: those tested in 2005 (any test 
in 2005), those eligible to be tested but not receiving a test 
in 2005 (not compliant and not tested in 2005), and those 
who did not need a CRC test (compliant — no test needed). 
We analyzed physician visits for 2 groups: those who were 
and were not tested in 2005. Because the data used for 
these analyses are population-based, we used descriptive 
rather than inferential statistics.
We used multivariate logistic regression to examine the 
relative importance of the number and type of physician 
visits on receipt of a CRC test in 2005. As measures of 
association between frequency and type of physician visits 
and receipt of a CRC test, we calculated adjusted odds 
ratios (ORs) with 95% confidence intervals (95% CIs). We 
present 3 models: Model 1, among all enrollees, in which 
we examine the association between number of visits and 
receipt of CRC testing; Model 2, conducted only for enroll-
ees who had 1 or more physician visits, in which we exam-
ine number of visits and physician specialty; and Model 3, 
among enrollees who had a primary care visit, in which 
we examine the relationship of number of visits and the 
type of primary care provider seen. We adjusted all mod-
els for enrollee age, race/ethnicity, sex, original reason for 
eligibility (age or disabling condition), entitlement status 
(state buy-in or no state buy-in), state of residence, and 
number of comorbid conditions. Entitlement status refers 
to eligibility for state Medicaid programs to pay Medicare 
premiums and serves as a marker for low income.
Results
The study included 1,108,424 North Carolina and South 
Carolina Medicare enrollees aged 65 to 85 (Table 1). Of 
these, 46.5% were not compliant and not tested in 2005; 
21.9% had a CRC test in 2005; and 31.6% were compliant 
with CRC tests and were excluded from further analyses. 
Of those who needed a CRC test in 2005 (n = 757,594), 68% 
did not receive one. Compared with enrollees who had any 
CRC test in 2005, those who did not receive a test were more 
likely to be of minority race or Hispanic ethnicity (20.4% vs 
14.4%); to have originally entered Medicare because of a 
disabling condition (11.1% vs 8.8%); and to be eligible for a 
state buy-in program (18.3% vs 10.3%). Those with no test 
in 2005 were more likely to be classified as unknown in 
terms of comorbid conditions (15.6% vs 4.4%), likely because 
of a limited number of health claims in 2004.
Lack of a physician visit during the previous year was 
higher among enrollees with no CRC tests compared with 
enrollees who had a CRC test in 2005 (19.8% vs 5.4%) 
(Table 2). Those not tested in 2005 had, on average, fewer 
physician visits than those who were tested (4.7 visits vs 7 
visits). Among enrollees who were not tested in 2005, 45% 
received care exclusively from primary care physicians 
(Table 3). Enrollees without a test in 2005 were less likely 
than enrollees with a test to have received care from both 
primary care and nonprimary care physicians (17% vs 
24%) and from physicians with primary care, nonprimary 
care, and mixed specialties (10% vs 18%).
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Of all Medicare patients who received care from at least 
3 different types of physicians (primary care, nonprimary 
care, and mixed-specialty physicians), only half had a CRC 
test in 2005 (Figure 1). Less than one-third of patients 
who had only primary care, nonprimary care, or mixed-
specialty visits had a CRC test.
Medicare patients with obstetrician/gynecologist visits 
were most likely to be tested in 2005 (47%), followed by 
patients who had seen physicians with multiple specialties 
(Figure 2). Patients who had visits with family or general 
practice physicians were least likely to be tested (29%). No 
primary care specialty was without missed opportunities: 
less than half of the patients with primary care visits in 
2005 had a CRC test, regardless of the primary care spe-
cialty of the physicians.
Model 1 (Table 4) revealed a strong, positive association 
between the number of visits and having a test, with a 
monotonic increase in the likelihood of having a CRC test 
as the number of visits increased. Enrollees with 1 to 5 
visits were more than twice as likely to have had a test as 
those with no visits (OR, 2.6; 95% CI, 2.6-2.7). Enrollees 
with 21 or more visits were 8 times as likely to have had a 
test as those with no visits (OR, 8.3; 95% CI, 7.9-8.6).
Model 2 (Table 4) showed that enrollees whose visits 
included contact with a primary care physician were sig-
nificantly more likely to be tested in 2005 than enrollees 
with nonprimary care visits. Odds ratios for all categories 
of physician visits that included primary care visits were 
significantly greater than 1. Although the number of visits 
remained an important predictor, the effect was attenu-
ated by type of physician included in the model.
In Model 3 (Table 4), enrollees who saw family or general 
medicine physicians were less likely to have had a CRC 
test (OR, 0.61; 95% CI, 0.60-0.62) than those who visited 
physicians with internal medicine, preventive medicine, or 
geriatric specialties. Enrollees who saw obstetrician/gyne-
cologists were more likely to have had a CRC test (OR, 
1.23; 95% CI, 1.17-1.29).
In all 3 models, demographic characteristics were sig-
nificantly associated with receipt of CRC test. Medicare 
enrollees who were older, minority race or Hispanic 
ethnicity, or male were less likely to be tested. Enrollees 
originally eligible because of disability and those entitled 
to state buy-in (a marker for low income) were also less 
likely to have had a CRC test. Enrollees with evidence 
of any comorbid conditions were less likely to have had 
a CRC test. State variation was also observed: enrollees 
from South Carolina were more likely to have had CRC 
tests than those from North Carolina.
 
Figure 2. Percentage of fee-for-service North Carolina and South Carolina 
Medicare enrollees who were seen by primary care physicians in 2005, cur-
rent with CRC testing, by primary care specialty 
Abbreviations: CRC, colorectal cancer; OB-GYN, obstetrics and gynecology; 
Prev Med, preventive medicine. 
 
Figure 1. Percentage of fee-for-service Medicare enrollees current with 
colorectal cancer (CRC) testing, by physician type, seen by any physician, 
North Carolina and South Carolina, 2005. 
a Physician categories: 1) primary care: internal medicine, family medicine, 
general practice, preventive medicine, geriatric medicine, obstetrician/gyne-
cologists, nurse practitioners, and physician assistants; 2) mixed specialty: 
physicians with more than 1 specialty listed, 1 of which was a primary care 
specialty; ) nonprimary care: physicians with only nonprimary care special-
ties.
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Discussion
Almost half (47%) of the Medicare population in 2 Southern 
states was in need of, and did not receive, a CRC test in 
2005, a finding consistent with earlier studies showing 
low CRC test use rates despite Medicare coverage (14-16). 
We found that having any physician office visit, increased 
number of office visits, and visits with primary care phy-
sicians were associated with increased CRC test use. We 
also found that a number of enrollees did not regularly 
see physicians, and many of those who did have physician 
contact remained untested.
We identified missed opportunities by all provider types to 
promote CRC testing. For most specialties, most of their 
Medicare patients were in need of a CRC test at the time 
of the visit and did not receive one. The characteristics of 
the untested group reveal a potentially vulnerable popu-
lation — those with Medicaid eligibility, who may have 
disabling conditions and multiple chronic conditions. Most 
are accessing medical care, but their access to preventive 
services remains “unrealized.” Our findings highlight the 
gap between coverage and receipt of CRC test and dem-
onstrate the influence of physician visits. We identify 3 
categories of Medicare enrollees who are untested: those 
with no visits, those with primary care visits, and those 
with visits to multiple types of physicians. This categori-
zation suggests that different strategies may be needed to 
improve CRC testing in each group.
Previous research has shown preventive or periodic health 
exams are associated with CRC test use (17). Yet, we 
found almost 20% of enrollees who needed a CRC test had 
no physician contact during the year of observation. In 
2011, Medicare will allow 1 annual wellness visit during 
which counseling on CRC screening could occur. However, 
prior experience indicates that coverage of a wellness visit 
by itself will not assure Medicare enrollees use it — in 
2006 and 2007, only 3% of enrollees used the “Welcome to 
Medicare” visit (18). Outreach to new Medicare enrollees, 
and “in-reach” to recall patients who have not recently 
been seen, may improve CRC testing rates (19).
As a stand-alone strategy, encouraging enrollees to visit 
primary care physicians may not result in substantial 
improvements in CRC testing at the population level (20). 
In our cohort, many enrollees remained untested regard-
less of the frequency of visits. Our findings are consistent 
with earlier studies reporting that contact with physicians 
is not sufficient to ensure that CRC testing will be com-
pleted (5,15,21,22). Greater understanding of tools and 
systems is needed to support physicians in the promotion 
of CRC testing. Factors identified as barriers to physicians 
offering CRC testing include the limited amount of time 
for a patient visit, competing priorities, and lack of office 
systems to facilitate screening (23-25). Increased CRC 
screening referrals have been documented through the use 
of simple tools such as chart stickers and reminders (26). A 
toolbox containing sample policies, reminder systems, and 
communication approaches is available from the National 
Colorectal Cancer Roundtable to assist physicians in 
increasing CRC testing (www.nccrt.org).
Physician attitudes toward cancer screening may vary by 
specialty. The higher rate of CRC testing we found among 
enrollees with an obstetrician/gynecologist visit is consis-
tent with findings from an earlier study showing signifi-
cantly higher rates of mammography referral for patients 
treated by obstetrician/gynecologists compared with other 
primary care physicians (27).
Although strategies to improve CRC testing typically 
target primary care physicians (28,29), we found that 
a combination of primary care and specialist visits was 
associated with increased CRC testing. A recent study 
reported that specialists spend a substantial portion of 
their time providing routine care and preventive services 
to their patients (30). Electronic health records (EHRs) 
offer potential for improving CRC testing among all 
physicians, including specialists, by alerting physicians 
to patients’ test status. EHRs could identify and recall 
patients for screening, remind office staff to counsel 
patients about screening, and monitor screening com-
pliance. An EHR system with the ability to exchange 
information across settings may be the only feasible way 
to manage the multiplicity of communication that needs 
to occur between the many physicians providing care to 
Medicare enrollees.
Study limitations and strengths
CRC testing rates are known to vary by geographic region 
(3,31,32). Different patterns may be observed in other loca-
tions. Current US Preventive Services Task Force recom-
mendations on CRC screening recommend against routine 
screening of people aged 76 to 85 (33). We included this age 
group in this study because we were targeting unscreened 
Medicare enrollees. CRC testing for some enrollees in this 
age group may not be appropriate.
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The strong associations observed between number and 
type of physician visits and receipt of CRC testing are open 
to several interpretations. They may represent causal 
relationships, meaning increasing the number and type of 
physician visits would raise CRC test rates. However, it is 
also possible the associations are driven by medical condi-
tions that cause patients to visit doctors more frequently 
or other characteristics that may independently lead to 
being tested for CRC.
Medicare data provide the opportunity to study a large 
population, examining care received from multiple provid-
ers to accurately measure CRC test status (12,13). They 
are not, however, without limitations. Tests conducted 
before patients enter Medicare are not available. Younger 
enrollees who had endoscopy before entering Medicare 
may not be due for another test. Additionally, we had 
access to claims from an 8-year window (1998-2005). 
Medicare enrollees who had colonoscopy during 1996 
through 1997 would be incorrectly classified in our data 
as untested. Medicare did not cover screening for CRC 
during that time period, and diagnostic test use was low. 
The effect of these data limitations is minimal, as our 
population-based rates compare favorably with rates from 
national surveys (3,34).
Conclusions
Increased CRC screening would reduce CRC death, but 
much work remains to be done to realize that ben-
efit. Working with the Medicare population to increase 
“realized” access for those with insurance may inform 
approaches to access as we move toward health insurance 
reform.
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Tables
Table 1. Characteristics of Fee-For-Service Medicare Enrollees, by Colorectal Cancer Test Status, North Carolina and South Carolina, 
2005
Characteristic
Not Compliant and Not Testeda 
(n = 515,193), No. (%)
Any Testb 
(n = 242,401), No. (%)
Compliant, No Test Neededc 
(n = 350,830), No. (%)
Age, y
5-7 299,20 (58.1) 18,2 (1.) 191,528 (5.)
75-85 215,989 (1.9) 9,79 (8.7) 159,02 (5.)
Race/ethnicity
White 09,9 (79.) 207,9 (85.) 29,18 (8.)
African American 97,1 (18.9) 2,25 (1.5) 51,079 (1.)
Asian 2,1 (0.5) 55 (0.2) 857 (0.2)
Hispanic 1,092 (0.2) 257 (0.1) 1 (0.1)
Native American 1, (0.) 72 (0.2) 80 (0.2)
Other 2,977 (0.) 1,089 (0.) 1,70 (0.)
Sex
Female 29,9 (57.2) 17,951 (1.0) 20,189 (58.2)
Eligibility reason
Aged 57,8 (88.9) 221,121 (91.2) 12,81 (89.2)
Disabled 57,0 (11.1) 21,280 (8.8) 7,989 (10.8)
Entitlementd
Medicare only 20, (81.7) 217,95 (89.7) 0,578 (8.5)
State buy-in 9,50 (18.) 2,90 (10.) 7,252 (1.5)
State
North Carolina 7,15 (5.) 15,90 (.) 21,0 (.0)
South Carolina 178,09 (.) 89,011 (.7) 119,200 (.0)
Comorbid conditionse
None 10,00 (0.) 17,89 (9.) 229,98 (5.5)
1 91,557 (17.8) 7,95 (19.8) 75,889 (21.)
≥2 2,1 (.) 15,9 (.) 0,5 (8.7)
Unknown 80,575 (15.) 10,588 (.) 1,19 (.1)
 
Abbreviation: FOBT, fecal occult blood test. 
a No claims-based evidence of a colonoscopy during 1998-2005, or a sigmoidoscopy or barium enema during 2000-2005, and no FOBT claim in 2005. 
b A claim for colonoscopy, sigmoidoscopy, barium enema, or FOBT in 2005. 
c Claims-based evidence of a colonoscopy during 1998-200, or a sigmoidoscopy or barium enema during 2000-200. 
d State buy-in indicates the enrollee is eligible for Medicaid to “buy” Medicare coverage. 
e Classified using Charlson index (11) modified for use with claims data. Categories indicate the number of Charlson conditions identified. Unknown indicates 
insufficient claims available to assess comorbidity.
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Table 2. Physician Office Visits by Fee-for-Service Medicare Enrollees, by Colorectal Cancer Test Status, North Carolina and South 
Carolina, 2005
No. of Physician Visitsa
Not Compliant and Not Testedb  
(n = 515,193), No. (%)
Any Testc  
(n = 242,401), No. (%)
0 101,879 (19.8) 1,025 (5.)
1-5 2,50 (7.) 10,80 (.1)
-10 112,919 (21.9) 7,17 (0.2)
11-15 ,219 (7.0) 29,9 (12.1)
1-20 12,11 (2.) 11,8 (.8)
≥21 7,55 (1.5) 8,1 (.)
Mean no. of visits .7 7.0
 
Abbreviation: FOBT, fecal occult blood test. 
a Visits to physicians with surgical, critical care, or other nonpatient-contact specialty are not included. The time window for counting visits varies by study 
group: for those not compliant and not tested in 2005, calendar year 200 claims were used; for those tested in 2005, a 12-month window ending with the 
month before their first test in 2005 was used. 
b No claims-based evidence of a colonoscopy during 1998-2005, or a sigmoidoscopy or barium enema during 2000-2005, and no FOBT claim in 2005. 
c A claim for colonoscopy, sigmoidoscopy, barium enema, or FOBT in 2005.
Table 3. Type of Physicians Seen by Fee-for-Service Medicare Enrollees With Any Visit, North Carolina and South Carolina, 2005
Type of Physician(s) Seen
Enrollees with any physician visit
Not Compliant and Not Testeda 
No. (%) (n = 413,314)
Any Testb 
No. (%) (n = 229,376)
Nonprimary care physicians only 1,1 (.) ,285 (1.9)
Primary care physicians only 188,052 (5.5) 75,51 (2.9)
Physicians with mixed specialty only 29,88 (7.1) 9,829 (.)
Primary care and mixed-specialty physicians 0,58 (1.) ,282 (15.8)
Primary care and nonprimary care physicians 8,90 (1.7) 5,08 (2.)
Physicians with mixed specialty and nonprimary care physicians 11,887 (2.9) 7,9 (.2)
Primary care, nonprimary care, and mixed-specialty physicians 0,958 (9.9) 1,979 (18.)
Enrollees with a primary care visit (n = 358,298) (n = 207,813)
Internal medicine, preventive medicine, geriatrics 10,851 (29.0) 9,289 (.)
Family and general practice 19,925 (1.8) 1, (29.7)
Obstetrician/gynecologist ,0 (1.0) ,12 (1.5)
Physician assistant or nurse practitioner 11,10 (.2) ,82 (2.)
Other (multiple specialties) 89,509 (25.0) 8,877 (.1)
 
Abbreviation: FOBT, fecal occult blood test. 
a No claims-based evidence of a colonoscopy during 1998-2005, or a sigmoidoscopy or barium enema during 2000-2005, and no FOBT claim in 2005. 
b A claim for colonoscopy, sigmoidoscopy, barium enema, or FOBT in 2005.
VOLUME 8: NO. 5
SEPTEMBER 2011
10 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2011/sep/10_0227.htm
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position  
of the Centers for Disease Control and Prevention.
Table 4. Influence of Number and Type of Physician Office Visits on Receipt of Colorectal Cancer Testing by Fee for Service Medicare 
Enrollees, North Carolina and South Carolina, 2005
Enrollee Characteristic
Model 1: All Enrollees 
(n = 757,594), 
OR (95% CI)a
Model 2: Enrollees With Any 
Physician Visit 
(n = 642,690), 
OR (95% CI)b
Model 3: Enrollees With a Visit 
to a Primary Care Physician 
(n = 566,111), 
OR (95% CI)c
Age, y 
5-9 1.0 [Referent]
70-7 1.18 (1.17-1.20) 1.19 (1.17-1.21) 1.20 (1.18-1.22)
75-79 1.02 (1.01-1.0) 1.02 (1.01-1.0) 1.02 (1.00-1.0)
80-85 0.70 (0.9-0.71) 0.70 (0.9-0.72) 0.9 (0.8-0.70)
Race/ethnicity
White 1.0 [Referent]
African American 0.8 (0.82-0.8) 0.90 (0.88-0.91) 0.85 (0.8-0.8)
Asian 0.9 (0.2-0.75) 0.9 (0.-0.77) 0. (0.59-0.7)
Hispanic 0.72 (0.-0.8) 0.71 (0.1-0.82) 0.71 (0.1-0.8)
Native American 0.80 (0.72-0.89) 0.8 (0.75-0.9) 0.78 (0.9-0.88)
Other Race 0.85 (0.79-0.91) 0.88 (0.81-0.95) 0.8 (0.77-0.91)
Sex 
Female 1.0 [Referent]
Male 0.90 (0.89-0.91) 0.91 (0.90-0.92) 0.98 (0.97-0.99)
Entitlementd 
No state buy-in 1.0 [Referent] 1.0 [Referent] 1.0 [Referent]
State buy-in 0.5 (0.5-0.55) 0.55 (0.5-0.5) 0.55 (0.5-0.5)
Eligibility reason 
Age 1.0 [Referent]
Disability 0.82 (0.80-0.8) 0.82 (0.80-0.8) 0.82 (0.81-0.8)
State of residence
North Carolina 1.0 [Referent]
South Carolina 1.12 (1.10-1.1) 1.09 (1.08-1.10) 1.15 (1.1-1.17)
Comorbid conditionse 
0 1.0 [Referent]
1 0.82 (0.81-0.8) 0.80 (0.79-0.82) 0.81 (0.79-0.82)
≥2 0.9 (0.8-0.71) 0.5 (0.-0.7) 0. (0.5-0.8)
Unknown 0.5 (0.-0.7) 2.2 (2.17-2.5) 1.95 (1.87-2.0)
 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable because variable not included in the model. 
a For Model 1, the association between number of visits and receipt of colorectal cancer testing was examined among all enrollees. 
b For Model 2, the association between number of visits and physician specialty were examined only for enrollees who had 1 or more physician visits. 
c For Model , the association between number of visits and the type of primary care provider seen was examined for enrollees who had primary care visits. 
d State buy-in indicates the enrollee is eligible for Medicaid to “buy” Medicare coverage. 
e Classified using Charlson index (11) modified for use with claims data. Categories indicate the number of Charlson conditions identified. Unknown indicates 
insufficient claims available to assess comorbidity. 
f Physician categories: 1) primary care: internal medicine, family medicine, general practice, preventive medicine, geriatric medicine, obstetrians/gynecolo-
gists, nurse practitioners and physician assistants; 2) mixed specialty: physicians with more than 1 specialty listed, 1 of which was a primary care specialty; ) 
nonprimary care: physicians with only nonprimary care specialties.
(Continued on next page)
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Enrollee Characteristic
Model 1: All Enrollees 
(n = 757,594), 
OR (95% CI)a
Model 2: Enrollees With Any 
Physician Visit 
(n = 642,690), 
OR (95% CI)b
Model 3: Enrollees With a Visit 
to a Primary Care Physician 
(n = 566,111), 
OR (95% CI)c
Number of visits
0 1.0 [Referent] NA NA
1-5 2.2 (2.55-2.9) NA NA
-10 .19 (.07-.1) NA NA
11-15 5.5 (5.8-5.8) NA NA
1-20 .91 (.-7.18) NA NA
≥21 8.27 (7.9-8.) NA NA
Number of visits  
1-5 NA 1.0 [Referent]
-10 NA 1.29 (1.27-1.1) 1.5 (1.51-1.55)
11-15 NA 1.5 (1.5-1.59) 2.02 (1.99-2.0)
1-20 NA 1.81 (1.7-1.87) 2. (2.7-2.51)
≥21 NA 2.07 (2.00-2.15) 2.87 (2.77-2.97)
Type of physicians seenf 
Nonprimary care only NA 1.0 [Referent] NA
Primary care only NA 1.2 (1.22-1.1) NA
Mixed specialties only NA 1.08 (1.0-1.12) NA
Primary care and mixed specialty NA 1.81 (1.7-1.88) NA
Primary care and nonprimary care NA 2.21 (2.1-2.0) NA
Mixed specialty and nonprimary care NA 1.8 (1.7-1.9) NA
Primary care, nonprimary care and mixed specialty NA 2. (2.5-.77) NA
Type of primary care physician 
Internal medicine, preventive medicine, or geriatrics 
only
NA NA 1.0 [Referent]
Family and general practice only NA NA 0.1 (0.0-0.2)
Obstetrician/gynecologist only NA NA 1.2 (1.17-1.29)
Physician assistant or nurse practitioner only NA NA 0.7 (0.-0.9)
Other (multiple specialties) NA NA 1.02 (1.00-1.0)
 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable because variable not included in the model. 
a For Model 1, the association between number of visits and receipt of colorectal cancer testing was examined among all enrollees. 
b For Model 2, the association between number of visits and physician specialty were examined only for enrollees who had 1 or more physician visits. 
c For Model , the association between number of visits and the type of primary care provider seen was examined for enrollees who had primary care visits. 
d State buy-in indicates the enrollee is eligible for Medicaid to “buy” Medicare coverage. 
e Classified using Charlson index (11) modified for use with claims data. Categories indicate the number of Charlson conditions identified. Unknown indicates 
insufficient claims available to assess comorbidity. 
f Physician categories: 1) primary care: internal medicine, family medicine, general practice, preventive medicine, geriatric medicine, obstetrians/gynecolo-
gists, nurse practitioners and physician assistants; 2) mixed specialty: physicians with more than 1 specialty listed, 1 of which was a primary care specialty; ) 
nonprimary care: physicians with only nonprimary care specialties.
Table 4. (continued) Influence of Number and Type of Physician Office Visits on Receipt of Colorectal Cancer Testing by Fee for 
Service Medicare Enrollees, North Carolina and South Carolina, 2005
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Appendix A. ICD-9 Codes Used to Identify and Exclude People Who Had Above Average 
Risk for Colorectal Cancer
Clinical condition ICD-9 Code
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum 159
Carcinoma in situ of colon 20.
Carcinoma in situ of rectum 20.
Regional enteritis 555
Ulcerative colitis 55
Diverticulitis 52.01, 52.0, 52.11, 52.1
 
Abbreviation: ICD-9, International Classification of Diseases, 9th Revision, Clinical Modification.
Appendix B. Procedure codes for identifying colorectal cancer tests
 
Type of Test ICD-9 Codes HCPCS Codes CPT Codes
Fecal occult blood test (FOBT) NA G0107 82270, 8227
Sigmoidoscopy 5.2 
5.2 
8.21-8.25
G010 500 
50 
505 
507–509 
527 
50 
51 
52 
5 
5 
57–59 
50 
51 
52 
55
Colonoscopy 5.21-5.2 
5.25
G0105 (high risk) 
G0121 (nonhigh risk)
555 
578 
579 
580 
581 
582–585 
58 
587 
88–9 
97
Double contrast barium enema NA G010 
G0120 
G0122
7270 
7280
 
Abbreviation: ICD-9, International Classification of Diseases, 9th Revision, Clinical Modification; HCPCS, Healthcare Common Procedure Coding System; CPT, 
Current Procedural Terminology.
 
